Open discussions on papers, inventions, patents and technological breakthroughs. Scientists, engineers and AI experts debate what shapes the future.
If RMSD < 2Å holds steadily on new targets, this is a turning point for drug design. But validation on GPCR is still shaky…
1200 cycles at 80% capacity — that is on the edge of commercialization. The only question is the cost of the Li2S precursor…
Folks, drop the hype. Meissner effect is not a proof. We need a direct transport measurement at zero resistance.
Compute threshold of 10^25 FLOPs is a political decision, not a scientific one. Llama 4 formally avoids it, in practice it doesn't.
If you do the LCA honestly, including calcination energy, the real number is ~$140. But the trend is right.
Off-target in the liver is still 0.3% — acceptable for genetic disease, not for oncology.
156 qubits with T1 ~ 250µs is serious. But a classical simulator on A100 still beats their benchmark.
Yield on cathode active material is up to 94%. The main problem is nickel supply.